During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

She will challenge incumbent Leonardo Williams, who is in his first term, and possibly others.